BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38309431)

  • 21. Aberrant Expression of Long Non Coding RNA HOTAIR and De-Regulation of the Paralogous 13 HOX Genes Are Strongly Associated with Aggressive Behavior of Gastro-Entero-Pancreatic Neuroendocrine Tumors.
    Di Mauro A; Scognamiglio G; Aquino G; Cerrone M; Liguori G; Clemente O; Di Bonito M; Cantile M; Botti G; Tafuto S; Tatangelo F
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34208964
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Islet-1 Is Differentially Expressed Among Neuroendocrine and Non-Neuroendocrine Tumors and Its Potential Diagnostic Implication.
    Xiang Y; Malik F; Zhang PJ
    Int J Surg Pathol; 2023 Oct; 31(7):1294-1301. PubMed ID: 37796752
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clusterin in Neuroendocrine Epithelial Neoplasms: Absence of Expression in a Well-differentiated Tumor Suggests a Jejunoileal Origin.
    Czeczok TW; Stashek KM; Maxwell JE; O'Dorisio TM; Howe JR; Hornick JL; Bellizzi AM
    Appl Immunohistochem Mol Morphol; 2018 Feb; 26(2):94-100. PubMed ID: 29420353
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of Sex Determining Region Y-Box 2 and Pancreatic and Duodenal Homeobox 1 in Pancreatic Neuroendocrine Tumors.
    Akiyama T; Shida T; Yoshitomi H; Takano S; Kagawa S; Shimizu H; Ohtsuka M; Kato A; Furukawa K; Miyazaki M
    Pancreas; 2016 Apr; 45(4):522-7. PubMed ID: 26491904
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CDX-2 homeobox gene product expression in neuroendocrine tumors: its role as a marker of intestinal neuroendocrine tumors.
    Barbareschi M; Roldo C; Zamboni G; Capelli P; Cavazza A; Macri E; Cangi MG; Chilosi M; Doglioni C
    Am J Surg Pathol; 2004 Sep; 28(9):1169-76. PubMed ID: 15316316
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of cadherin 17 in well-differentiated neuroendocrine tumours.
    Snow AN; Mangray S; Lu S; Clubwala R; Li J; Resnick MB; Yakirevich E
    Histopathology; 2015 Jun; 66(7):1010-21. PubMed ID: 25388236
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Insulinoma-associated protein 1 immunostaining on cytology specimens: an institutional experience.
    Rodriguez EF; Fite JJ; Chowsilpa S; Maleki Z
    Hum Pathol; 2019 Mar; 85():128-135. PubMed ID: 30502379
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Consensus-Developed Morphological Re-Evaluation of 196 High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms and Its Clinical Correlations.
    Elvebakken H; Perren A; Scoazec JY; Tang LH; Federspiel B; Klimstra DS; Vestermark LW; Ali AS; Zlobec I; Myklebust TÅ; Hjortland GO; Langer SW; Gronbaek H; Knigge U; Tiensuu Janson E; Sorbye H
    Neuroendocrinology; 2021; 111(9):883-894. PubMed ID: 33002892
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunohistochemical Characterization of the Origins of Metastatic Well-differentiated Neuroendocrine Tumors to the Liver.
    Yang Z; Klimstra DS; Hruban RH; Tang LH
    Am J Surg Pathol; 2017 Jul; 41(7):915-922. PubMed ID: 28498280
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Value of Islet 1 and PAX8 in identifying metastatic neuroendocrine tumors of pancreatic origin.
    Koo J; Mertens RB; Mirocha JM; Wang HL; Dhall D
    Mod Pathol; 2012 Jun; 25(6):893-901. PubMed ID: 22388755
    [TBL] [Abstract][Full Text] [Related]  

  • 31. APOBEC3B High Expression in Gastroenteropancreatic Neuroendocrine Neoplasms and Association With Lymph Metastasis.
    Feng C; Zheng Q; Yang Y; Xu M; Lian Y; Huang J; Jiang Y
    Appl Immunohistochem Mol Morphol; 2019 Sep; 27(8):599-605. PubMed ID: 30095460
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recent classifications systems for gastroenteropancreatic neuroendocrine tumors A single-center experience.
    Yagmur Y; Söğutcü N; Gümüş S
    Ann Ital Chir; 2020; 91():598-604. PubMed ID: 32989209
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High VEGF serum values are associated with locoregional spread of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
    Cigrovski Berković M; Čačev T; Catela Ivković T; Marout J; Ulamec M; Zjačić-Rotkvić V; Kapitanović S
    Mol Cell Endocrinol; 2016 Apr; 425():61-8. PubMed ID: 26805636
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cdx2 as a marker for neuroendocrine tumors of unknown primary sites.
    Erickson LA; Papouchado B; Dimashkieh H; Zhang S; Nakamura N; Lloyd RV
    Endocr Pathol; 2004; 15(3):247-52. PubMed ID: 15640551
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnostic imaging approach to gastro-entero-pancreatic carcinomas of neuroendocrine origin - single NET center experience in Poland.
    Cwikla JB; Nasierowska-Guttmejer A; Jeziorski KG; Cichocki A; Zgliczynski W; Stepień K; Seklecka N; Durlik M; Malkowski B; Walecki J
    Neuro Endocrinol Lett; 2007 Dec; 28(6):789-800. PubMed ID: 18063942
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
    Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
    Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human epididymis protein 4 (HE4) is a novel immunohistochemical marker of neuroendocrine differentiation.
    Su W; Yang K; Jiang H; Song H; Feng K; Li Q
    Virchows Arch; 2022 Sep; 481(3):433-441. PubMed ID: 35913578
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The eye of the beholder: orbital metastases from midgut neuroendocrine tumors, a two institution experience.
    Das S; Pineda G; Goff L; Sobel R; Berlin J; Fisher G
    Cancer Imaging; 2018 Dec; 18(1):47. PubMed ID: 30522522
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Subset of Large Cell Neuroendocrine Carcinomas in the Gastroenteropancreatic Tract May Evolve from Pre-existing Well-Differentiated Neuroendocrine Tumors.
    Pelosi G; Bianchi F; Dama E; Metovic J; Barella M; Sonzogni A; Albini A; Papotti M; Gong Y; Vijayvergia N
    Endocr Pathol; 2021 Sep; 32(3):396-407. PubMed ID: 33433886
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SATB2 is a sensitive marker for lower gastrointestinal well-differentiated neuroendocrine tumors.
    Li Z; Yuan J; Wei L; Zhou L; Mei K; Yue J; Gao H; Zhang M; Jia L; Kang Q; Huang X; Cao D
    Int J Clin Exp Pathol; 2015; 8(6):7072-82. PubMed ID: 26261600
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.